Long-term outcomes with balloon-expandable and self-expandable prostheses in patients undergoing transfemoral transcatheter aortic valve implantation for severe aortic stenosis.

Vollenbroich, René; Wenaweser, Peter Martin; Macht, Annina; Stortecky, Stefan; Praz, Fabien; Rothenbühler, Martina; Roost, Eva; Hunziker, Lukas; Räber, Lorenz; Windecker, Stephan; Pilgrim, Thomas (2019). Long-term outcomes with balloon-expandable and self-expandable prostheses in patients undergoing transfemoral transcatheter aortic valve implantation for severe aortic stenosis. International journal of cardiology, 290, pp. 45-51. Elsevier 10.1016/j.ijcard.2019.03.050

	Text Vollenbroich IntJCardiol 2019.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (574kB) | Request a copy
Preview	Text Vollenbroich IntJCardiol 2019_epub_postprint.pdf - Accepted Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (582kB) | Preview

BACKGROUND

Data on long-term outcomes in patients undergoing transcatheter aortic valve implantation (TAVI) is scarce.

METHODS

We investigated long term outcomes of consecutive patients undergoing TAVI with balloon- and self-expandable bioprostheses (Edwards SAPIEN (ESV), Edwards Lifesciences Inc., Irvine, CA, USA; Medtronic Corevalve system (MCS), Medtronic Inc., Minneapolis, MN, USA).

RESULTS

Among 628 patients (mean age 82.4 ± 5.8 years, 55% female), 489 (77.8%) underwent transfemoral TAVI. 309 (63.2%) patients received a MCS prosthesis, whereas 180 (36.8%) patients were treated with an ESV prosthesis. The median duration of follow-up amounted to 5.2 years (range 3.4-8.3 years). All-cause mortality did not differ between the two groups (MCS 46.9%, ESV 53.4%, CI 95%: RR 1.21 [0.93-1.57], P = 0.15), whereas cardiac mortality was higher in the ESV cohort after 5 years of follow-up (MCS 35.1%, ESV 45.4%, CI 95%: RR 1.37 [1.01-1.86], P = 0.04). Structural valve deterioration, which was on average diagnosed 41.9 months (range 18-60 months) after TAVI, occurred in 8 cases (1.6%), resulting in one repeat intervention.

CONCLUSIONS

While half of all patients died within 5 years after TAVI with no significant differences in all-cause mortality, structural valve deterioration was documented in <2% of cases.

Interest & Impact

Downloads

188 since deposited on 25 Apr 2019
7 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item